Our 2021 Diabetes Forum, hosted by TCOYD and diaTribe, featured engaging discussions on the following topics:
- The hottest trials and data revealed at this year’s ADA Symposium
- The latest ADA Standards of Care and CVOT/DKD treatment algorithm updates
- Recent updates on the SGLT2 inhibitors: CHF and renal protection
- High dose GLP1-RAs, dual and triple agonists in development
- Advances in drug delivery systems
- The latest in CGM, pumps, hybrid closed looped and fully closed AP systems
- TIR and other analytics that have and will become important
- Advances in pramlintide formulations, glucagon, including glucagon receptor antagonists
- Cure-based immune therapies for T1D
- Telehealth/digital diabetes care apps
Watch the panel discussion below, and a full list of the Q&A can be found here.
Leave a Reply